Q3 FY2026 · ended Sep 30, 2026 · Revenue $230.22M, -20.1% YoY · Filed Nov 5, 2026
Trulieve Cannabis Corp. (TRLV) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $230.2 million and net income of $774,000. Free cash flow was $10.9 million. As of Sep 30, 2026 it held $326.7 million in cash and investments and $368.4 million in total debt.
Revenue
$230.22M
-20.1% vs year-ago quarter
Net income
$774,000
+102.7% vs year-ago quarter
Operating cash flow
$74.42M
-2.6% vs year-ago quarter
Free cash flow
$10.90M
-78.8% vs year-ago quarter
EPS
$0.00
+100.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
170.60M
-10.7% vs year-ago quarter
Net cash
$-41.76M
Q3 FY2026
Operating margin
-25.6%
TTM
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- TRLV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Tallahassee, FL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1754195
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $230.2M | $271.0M | $286.8M | $293.1M | $288.2M |
| Operating income | $42.5M | -$370.5M | $35.7M | $15.3M | $42.2M |
| Net income | $774,000 | -$406.1M | $2.3M | -$43.6M | -$28.8M |
| Diluted EPS | $0.00 | -$2.11 | $0.01 | -$0.22 | -$0.14 |
| Operating cash flow | $74.4M | $53.1M | $55.7M | $59.2M | $76.4M |
| Free cash flow | $10.9M | $32.1M | $42.2M | $50.0M | $51.4M |
| Total assets | $2.1B | $2.1B | $2.8B | $2.7B | $2.9B |
| Total liabilities | $1.3B | $1.3B | $1.6B | $1.6B | $1.8B |
| Stockholders' equity | $771.5M | $765.9M | $1.1B | $1.1B | $1.2B |
| Cash and investments | $326.7M | $325.4M | $352.9M | $255.5M | $449.2M |
| Total debt | $368.4M | $362.9M | $398.7M | $332.5M | $565.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Regulation FD disclosure
|
Aug 7, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 5, 2026 | Aug 5, 2026 |
All 416 Trulieve Cannabis Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.